Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis
复制标题
非小细胞肺癌切除患者中CDK5/p35的表达：与预后的关系
DOI：
10.1007/s12032-010-9510-7
复制
发表时间：
2011-09-01
期刊：
影响因子：
3.4
通讯作者：
Wu, Gang
中科院分区：
文献类型：
--
作者：
Liu, Jun-Li;Wang, Xiao-Yan;Wu, Gang
这些非小细胞肺癌(NSCLC)患者的总体预后仍然很差。近年来，多项研究表明，细胞周期蛋白依赖性激酶-5(CDK5)的活性及其特异性激活蛋白p35在不同类型肿瘤的自发转移中起重要作用。我们的目的是探讨CDK5在非小细胞肺癌患者中的表达及其预后指标。应用免疫荧光染色方法检测95例非小细胞肺癌患者和20例肺部良性疾病患者肺组织中CDK5/p35的表达。探讨CDK5/p35的表达与非小细胞肺癌临床病理特征的关系。采用Kaplan-Meier法对CDK5/p35表达水平不同的肿瘤患者的5年总生存期进行评估。95例NSCLC中66例(69.5%)肿瘤细胞CDK5/p35表达阳性。CDK5/p35的表达与NSCLC患者的年龄、性别、病理类型无关，但与NSCLC的分化程度、病理分期及有无淋巴结转移有关。此外，CDK5/p35表达阳性和阴性患者的中位生存期分别为24个月和58个月，5年总生存率分别为25.8%和48.3%(P<；0.05)。CDK5/p35阳性的肺癌患者预后比CDK5/p35阴性的患者差。根据我们的结果，CDK5/p35可能是非小细胞肺癌患者预后的生物标志物。
Overall outcome of those patients with non-small cell lung cancer (NSCLC) remains poor. Recently, several studies demonstrated that cyclin-dependent kinase-5 (CDK5) activity with its specific activator protein p35 was important for spontaneous metastasis in various types of carcinomas. Our objective was to explore the expression of CDK5 and its prognostic indicator in patients with NSCLC. Immunofluorescent staining was used to detect the expression of CDK5/p35 in the lung tissue of 95 patients with NSCLC and 20 patients with benign pulmonary disease. The correlation between the expression of CDK5/p35 and clinicopathologic features of patients with NSCLC was investigated. The 5-year overall survival of patients with tumors expressing different levels of CDK5/p35 was evaluated by the Kaplan-Meier method. Positive expressions of CDK5/p35 were detected in the tumor cells in 66 samples (69.5%) of the 95 patients with NSCLC. Although no remarkable correlation between CDK5/p35 expression and age at the time of surgery, gender, and histopathologic type, there were significant differences between CDK5/p35 expression and degree of differentiation, pathological stage and lymph node metastasis in patients with NSCLC. In addition, we demonstrated that median survival for patients with and without CDK5/p35 expression was 24 and 58 months, respectively, and 5-year overall survival rate 25.8 and 48.3%, respectively (P < 0.05). Patients with lung cancer with a positive CDK5/p35 expression had a poorer prognosis than those with a negative CDK5/p35 expression. Based on our results, CDK5/p35 may represent a biomarker for prognosis in patients with NSCLC.